Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phage Therapy vs Silver Sulfadiazine for Burn Wound Infections
NCT02116010Phase 2Unknown
- Sponsor
- PHAXIAM Therapeutics
- Start
- Jul 2015
- Primary completion
- Jul 2016
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 3
01
Overview
A Phase 2 trial of PP1131, escherichia coli bacteriophage cocktail in burn wound infection, sponsored by PHAXIAM Therapeutics. Status: unknown.
02
Drugs
PP1131escherichia coli bacteriophage cocktail
03
Conditions
burn wound infection
Beyond the preview
Go deeper on NCT02116010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116010.